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Objective: Familial Urothelial cell bladder cancer is rare. We report two families with urothelial cell carcinoma (UCC)
of bladder with family history in other relatives, displaying probable autosomal dominant inheritance and a late
onset pure UCC phenotype, and document the phenotype in each family.
Methods: Descriptive familial study on two pedigrees over three generations.
Results: Two families with UCC bladder were identified, and the phenotype documented, each family having three
cases of late onset UCC.
Conclusion: Some cases of UCC are hereditary and may display autosomal dominant inheritance with late onset of
the cancer. Clinicians should be aware of the existence of a familial late onset UCC phenotype when managing
cases of UCC.
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Urothelial cell carcinoma (UCC) of bladder is common.
The main aetiological factors identified are cigarette
smoking and certain occupational exposures. Familial
UCC bladder is rare and infrequently encountered. Docu-
mented cases of familial UCC bladder in the medical litera-
ture are rare (Fraumeni and Thomas 1967; McCullough
et al. 1975; Ilic et al. 2011) and display early onset. Some
families with hereditary non-polyposis colon cancer
(HNPCC) in particular due to MSH2 mutations, can
also include cases of UCC bladder (van der Post et al.
2010), although these are predominantly upper tract
UCC, but often cases reported in the literature have not
been checked for HNPCC. We present two families with
pure UCC bladder and a late onset phenotype suggesting
that some types of UCC bladder may be late onset and
autosomal dominant in nature.* Correspondence: patrick.morrison@belfasttrust.hscni.net
3Department Genetic Medicine, Belfast HSC Trust, Lisburn Road, Belfast BT9
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Detailed analysis of two families with three or more
cases of urothelial cell cancer of the bladder was carried
out. Neither family had any significant relevant occupa-
tional or environmental exposure. Smoking history was
negative except where listed.
Family A. Three cases of UCC in the same sibship
presented. All were smokers in youth only. The male
proband II.1 was diagnosed with WHO stage III UCC at
76 years old, his brother II.4 with stage II UCC at
73 years and his sister II.7 with stage I UCC at 60 years.
A sister II.9 had breast cancer at 73 years and a sister
II.6 had a basal cell skin cancer at 80 years. Their father
I.1 died of heart disease at 61, and mother I.2 of ‘old
age’ at 86. No parental siblings had a history of any rele-
vant cancer (Figure 1).
Family B. A male proband II.1 was diagnosed with
UCC bladder at 60 years. Staging is not recorded. Two
siblings II3 and II.4, developed liver cancer due to com-
plications of hereditary ferritinaemia (HFE). The pro-
band’s daughter III.1 developed stage III bladder cancer
aged 76, a son III.6 was diagnosed with stage II UCC
bladder at age 50 (also a HFE gene carrier) a daughtern Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Figure 1 Three generation pedigree of family A. Bladder cancer shown as shaded. - indicates other cancer.
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son III.5 developed colon cancer at age 60 (Figure 2).
None of the bladder cases were known smokers.
Investigation and results
Genetic testing in the form of peripheral blood karyo-
type and array cytogenetic analysis was normal in each
proband. Immunohistochemical analysis for tumour ex-
pression of mismatch repair proteins MLH1, MSH2,
MSH6 and PMS2 was normal in the proband in each
family.
Discussion
The occurrence of two families with three or more affected
cases with UCC is extremely rare. There is no evidence thatFigure 2 Four generation pedigree of family B. Bladder cancer shown athe two families are related. The most likely mode of inhe-
ritance in both families is autosomal dominant, with the
father in family A possibly dying before symptoms de-
veloped. Autosomal recessive inheritance would also be
possible in family A and cannot be excluded. Familial
TCC is not widely documented; however the few docu-
mented familial cases in three families identified in the
older literature show much earlier onset of disease than in
our families (Fraumeni and Thomas 1967; McCullough
et al. 1975; Ilic et al. 2011). Mueller et al. reviewed cases of
UCC and identified two cases of later onset UCC with a
similar phenotype to our cases (Mueller et al. 2008), with
normal testing for HNPCC genes.
DNA has been stored on key siblings for the future
identification of candidate genes. So far, no dominantlys shaded. - indicates other cancer.
Brown et al. SpringerPlus 2014, 3:281 Page 3 of 4
http://www.springerplus.com/content/3/1/281inherited genes have been implicated in late onset UCC;
the interaction between genetic and environmental factors
makes their identification challenging. Polymorphisms in
genes involved in metabolism of environmental toxins are
known to modify individual susceptibility (McCullough
et al. 1975).
All the cases we describe have a later onset UCC
bladder phenotype. It is unclear whether the other can-
cers in family B are related or more likely are sporadic
occurrences. Urothelial cancers are estimated to occur
in up to 18% of MSH2 gene carriers (van der Post et al.
2010; Skeldon et al. 2013), although these are predomin-
antly upper tract TCC rather than bladder although
bladder cancers have been reported rarely and with male
predominance. Neither of our families had abnormal
mismatch repair proteins on immunohistochemistry.
Somatic mutations have been identified in bladder can-
cers with around 50–60% of cases showing mutations in
FGFR3 (Balbás-Martínez et al. 2013). Other genes in-
cluding STAG2 on the X-chromosome (Solomon et al.
2013) have been recognised, but no germline mutations
as yet identified in a pure bladder cancer phenotype.
Screening
A family history of UCC causes a two-fold increase
(Fraumeni and Thomas 1967; McCullough et al. 1975),
in the risk of its occurrence among first degree rela-
tives. The risk is less for more distant relatives. The
risk is exacerbated by environmental exposures, par-
ticularly smoking, and relatives should be made aware
of this.
There is no active screening programme at present
for such cases. We have advised relatives in these fam-
ilies to watch closely for symptoms of bladder cancer,
(e.g. haematuria), and seek urgent medical attention if
any symptoms occur. We recommend regular scree-
ning cystoscopy every 3 years, from the 5th decade.
Haematuria, or other suspicious symptoms, should
prompt discussion with a general practitioner and re-
ferral for urgent cystoscopy if needed. Careful taking
of a family history and testing for mismatch repair
protein tumour immunoexpression may help identify
or exclude HNPCC as a cause. In both families, the
later onset cases had a higher stage of bladder cancer,
and the screened siblings were identified at an earlier
age and earlier staging. Treatment was not materially
different from sporadic cases. Screening of family
members may allow earlier detection of bladder can-
cers at an earlier stage and improve treatment options
and success of treatment.
Conclusion
UCC bladder may occur with familial autosomal do-
minant inheritance. We describe two additional familiesto the existing two late onset HNPCC negative fa-
milies in the literature (Mueller et al. 2008), con-
firming a autosomal dominant phenotype distinct
from early onset UCC. We suspect that a small pro-
portion of urothelial cell carcinomas of the bladder
may have a strong family history. Clinicians should
take a thorough family history in cases of bladder
cancer and should be aware that some familial cases
may present with a later age at onset and incomplete
penetrance.
Further research in this area may identify candidate
genes, and improve the understanding of the patho-
genesis of UCC and, ultimately, lead to improvements
in screening and treatment if testing for germline
UCC bladder cancer mutations becomes possible.
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